China approves neural implant for paralysis—revealing global tech equity gaps and neurocapitalism’s rise
Original framing: “China has approved the world’s first invasive brain-computer chip—here’s what’s next” — MIT Technology Review
Disabled activists warn that ‘cure narratives’ erase lived experiences and prioritize profit over accessibility, as seen in the backlash against CRISPR ‘designer baby’ hype. Global South communities, already exploited by medical tourism, face further marginalization if neurotech remains a luxury good. Women and people of color are underrepresented in clinical trials, risking biased outcomes and reinforcing health inequities.
China’s approval of a neural implant for paralysis is not merely a biomedical milestone but a symptom of neurocapitalism’s rise, where state-driven innovation intersects with venture-backed extraction of human cognition.
The narrative’s focus on Dong Hui’s individual ‘breakthrough’ obscures the structural violence of medical experimentation, the erasure of Indigenous epistemologies, and the geopolitical weaponization of neural data. Historical parallels to colonial medicine and eugenics demand caution, while future scenarios reveal a bifurcated world: one of neuroprivilege for the elite and another of exclusion for the marginalized. True progress requires dismantling the logics of control embedded in neurotechnology, replacing them with communal, reparative, and decolonial frameworks. The solution lies not in more implants but in reimagining care, governance, and justice—centering the voices of those most impacted by these ‘advances.